Insider trade

Chair sold ~$9.41M of VRTX shares in the open market

Traded Nov 14, 2025 · Filed Nov 17, 2025

~$9.41M
Reported value · 21K sh @ $441.35: 24K
Holds after · shares reported: +15.2%
stock since the trade · S&P 500 +15.3%, $437.15 → $503.50 on Oct 5

Why it stands out

Vertex Pharmaceuticals's Executive Chairman sold $9.41M of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 14, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 17, 2025

Chair$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$9,413,996

Shares × reported transaction price

Timing vs results

11 days after results of Nov 3, 2025, 90 days before results of Feb 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $437.15 on Nov 14, 2025, 19% above its 52-week low and 15% below its high, after an 8% rise over the previous 30 trading days

52-week range $366.54 (Aug 8, 2025) to $513.76 (Mar 17, 2025), 48% of the way up, from 250 adjusted closes. 30 trading days earlier: $403.30 on Oct 3, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.3%	+2.3%	-3.6%
30 days	+2.7%	+2.5%	+0.2%
90 days	+9.6%	+3.5%	+6.2%
180 days	+0.2%	+11.9%	-11.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0000875320-25-000234
Filed / recorded: Nov 17, 2025, 9:12 PM UTC
Added to OQRO: Oct 2, 2026, 12:29 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: VERTEX PHARMACEUTICALS INC / MA
Issuer CIK: 875320
Ticker: VRTX
Reporting person: Jeffrey M Leiden
Relationship: Director, Officer
Officer title: Executive Chairman
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 14, 2025
Transaction code: S
Shares / units: 21,330
Price per share: $441.35
Acquired / disposed: Disposed (D)
Shares owned after: 24,066
Ownership form: Direct
Amendment: No

Footnotes from the filing

Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99).

Around the same time

Officer sold ~$3.16M of Vertex Pharmaceuticals

Scheduled in advance10mo ago

Officer sold ~$3.23M of Vertex Pharmaceuticals

Scheduled in advance10mo ago

Officer sold ~$2.02M of Vertex Pharmaceuticals

Scheduled in advance10mo ago